Human PlGF Antibody

R&D Systems, part of Bio-Techne | Catalog # MAB111991

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
MAB111991-100
MAB111991-SP
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Species Reactivity

Human

Applications

ELISA

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG2B Clone # 1038925

View all PlGF Antibodies »

Product Specifications

Immunogen

CHO-derived human PlGF-2 protein
Leu19-Arg170
Accession # NP_002623

Specificity

Detects human PIGF-1,2,3 and 4 in direct ELISAs.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG2B

Applications for Human PlGF Antibody

Application
Recommended Usage

ELISA

This antibody functions as an ELISA capture antibody when paired with human anti-PlGF-2 Monoclonal Antibody (Catalog # MAB11199).This product is intended for assay development on various assay platforms requiring antibody pairs.
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.  *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: PlGF

Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines (1 ‑ 3). Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF‑1), 152 (PlGF‑2), and 203 (PlGF‑3) amino acids (aa) respectively (1 ‑ 3). Only PlGF‑2 contains a highly basic heparin‑binding 21 aa insert at the C‑terminus (1). In the mouse, only one PlGF that is the equivalent of human PlGF‑2 has been identified (3). Human PlGF‑2 shares 60%, 56%, 82%, 95% and 95% aa identity with mouse, rat, canine, equine and porcine PlGF‑2. PlGF is mainly found as a variably glycosylated, secreted, 55 ‑ 60 kDa disulfide linked homodimer (4). Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells (1, 5 ‑ 7). Circulating PlGF increases during pregnancy, reaching a peak in mid‑gestation; this increase is attenuated in preeclampsia (8). However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia (9). PlGF binds and signals through VEGF R1/Flt‑1, but not VEGF  R2/Flk‑1/KDR, while VEGF binds both, but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, resulting in a PlGF inhibition of VEGF/VEGF R1 binding coupled to a subsequent promotion of VEGF/VEGF R2‑mediated angiogenesis (1, 5, 9, 10). However, PlGF (especially PlGF‑1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2 (4, 5). PlGF‑2, like VEGF164/165, shows heparin‑dependent binding of neuropilin (Npn)‑1 and Npn‑2, and can inhibit nerve growth cone collapse (11, 12). PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, and also contribute to inflammation in active sickle cell disease and atherosclerosis (6, 7, 9, 13 ‑ 16). Circulating PlGF often correlates with tumor stage and aggressiveness, and therapeutic PlGF‑2 antibodies are being investigated for their ability to inhibit tumor growth and angiogenesis (5, 13).

References

  1. Hauser, S. and H.A. Weich (1993) Growth Factors 9:259.
  2. Maglione, D. et al. (1993) Oncogene 8:925.
  3. DiPalma, T. et al. (1996) Mamm. Genome 7:6.
  4. Eriksson, A. et al. (2002) Cancer Cell 1:99.
  5. Ribatti, D. (2008) Angiogenesis 11:215.
  6. Oura, H. et al. (2003) Blood 101:560.
  7. Roncal, C. et al. (2010) Cardiovasc. Res. 86:29.
  8. Levine, R.J. et al. (2004) N. Engl. J. Med. 350:672.
  9. Carmeliet, P. et al. (2001) Nat. Med. 7:575.
  10. Autiero, M. et al. (2003) Nat. Med. 9:936.
  11. Migdal, M. et al. (1998) J. Biol. Chem. 273:22272.
  12. Cheng, L. et al. (2004) J. Biol. Chem. 279:30654.
  13. Fischer, C. et al. (2008) Nat. Rev. Cancer 8:942.
  14. Perelman, N. et al. (2003) Blood 102:1506.
  15. Cianfarani, F. et al. (2006) Am. J. Pathol. 169:1167.
  16. Maes, C. et al. (2006) J. Clin. Invest. 116:1230.

Long Name

Placenta Growth Factor

Alternate Names

PGF, PGFL

Entrez Gene IDs

5228 (Human); 18654 (Mouse)

Gene Symbol

PGF

UniProt

NP_002623 (Human)

Additional PlGF Products

Product Documents for Human PlGF Antibody

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Human PlGF Antibody

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.